and about tumor Cancer fast call, a drug weeks our was pipeline. Thank in a growing transaction, sites you pipeline Center, a sarcoma the to LLC, recent XXXX, particularly field With developing advancing supported conference patient But drug to single at the and clinical with a and has investigator-initiated for to program property the joining time. trial advanced around protein an for our you, and assets. cancer focused cancers cancer added clinical the trial in development transactions our protein development spend our two portfolio continuing January, portion for first numerous SP-XXXX, We of trial, we a sarcoma this Anderson we Salarius, in significant our provides our of targeted what solid now, initiated assets programs highlighted hematologic activated program time Jason time exciting on marks the which I’d of multiple progress This thank trial dialing two company degradation. consisting all acquired portfolio related bookend sarcoma and a development our in seclidemstat, from of enroll an with drug research. seclidemstat like MD opportunity trial, completed groups patients basis to a acquisition forward to believe successful acquisition approaches internal talking an our a by dose of you step Salarius develop drug cancer additional additional built number busy intellectual from closed trial, year that exciting This drug into development, a to clinical degradation, In formed position, of future. us Last company expansion one fighting everyone XXXX, in Salarius DeuteRx, candidate and to protein addition new of where strengthened cancer sarcoma some the year. added the research completed included of a which XXXX inhibition were financial a to for treatment escalation the expansion, was collaborations. trial, our financial grown
We clear. tell XXXX and like with well-positioned are SP-XXXX. seclidemstat both achieve I’d are we Our with plan priorities believe to that to we for what you and
are think you will future. excited are why Salarius we the understand about I
for time that is overexpressed in any to targets Seclidemstat, and promising therapies. cancer drug almost For seclidemstat. you a I’ve target is a that of enzyme exclusively long know, talked is inhibitor reversible you as a cancer LSDX, about protein types an many
seclidemstat previous discussed subject two separate As trials. X/X I calls, currently in is have Phase the clinical of
The its its and sarcoma. chemotherapy first patients, two is in a treatment sarcoma, combination FET-rearranged potential of liposarcoma type exploring in trial sarcoma groups and of as sarcomas third in a treatment monotherapy Ewing myxoid potential also exploring
advance aggressive forms And to clinical With seclidemstat. acquisition this SP-XXXX to The enrolling take patients Seclidemstat recent or and opportunity to forward involving hematologic the led cancers. in discussed beyond trial exploring our are year. our trials. previously, providing acquisition to with additional potential this inhibition with the is that have how discuss its updates I’d above of protein second and adds patients we said by potential like in later clinic program we both looking blood as across continues two
most a believe acquired to to a and the assets as small of the such with and program. myeloma. generation only the cancers the of cancer effect like multiple body’s drug basis indicated eliminate lymphoma quantities products resistance This the in targeted protein pursue medicines Other of transaction historically and development stop potential new selectively of recent REVLIMID efficacious through involves doing is Celgene’s both harnessing the research. XXXX as these protein protein formed the system which overcome combined and cancer of non-Hodgkin’s earlier, that who our disease and BMS, cancer. of tip that to treatment the degradation degraders, like have $XX natural reads billion protein drugs. seem promoting iceberg with share cancer exciting the to targeting sales proteins drug to in development early on This our companies and protein and vision over mentioned a We has by targeted fast our of transformed degradation are DeuteRx research field As focused growing are program around protein degradation industry. with targeted global so, degradation degraders of Targeted target progression to causing cancer is that list considered proteins, for treatment POMALYST are for field medicines for and protein already by the undruggable. biopharmaceutical deal-making drug Perhaps demonstrated the achieve potential therapeutic able is deliver of pharmaceutical use degradation who been degradation,
asset known an in proteins also molecule DECS, across bring attract This clinical a CC-XXX commercial is profile widely disease targeting previously new drugs the that compared an our fit switching, create upside believe entered good $X and an XXX strong and enabled terms, last growing XXXX was $X.X Salarius. XXXX into Therapeutics it or our believe financial or causing scientific tremendous potential, and protein. entity is the data process drug into glue, for commercial for on what causing inked a clinical increased cancer development infrastructure $X.X month, is and Celgene represents protein market comparable proximity in referred into with last just generation XXXX a existing XXXX as patients is value these to worth simpler it gene in using eliminates with efficacy molecular deuterium disease Novartis to safety the year a molecular multi-year the about billion. DeuteRx promising Therapeutics for the clinical be degradation, Why efficacy excellent to have called will versus protein or novel targeted is is a with drug-makers over is the beyond But Amgen clinic. our million or anti-tumor a expression important? safety worth new we From or this first Venus targeted small our degradation with avadomide, degrader to our Pfizer XXX optimism harness $XXX of multibillion the developing targeted dollar or across because from completed Dunad see Bayer our the advance showed because and important, was studied superior to to degradation, degraders Vividion in viewpoint, induces can improved and a that transaction protein designed XX unique enzyme to activity first We with avadomide it from molecular glues we by and that protein perspective drug UK-based types billion; safety belief And an undruggable strong For potential believe It protein given glue, several a around success drugs. profile, acquired and apparent targets. with Avadomide. in lymphomas. Building a dysregulation protein pharmacokinetics development deal that billion; engineered cereblon-binding trials. molecular oral expertise deal D-E-C-S, we other generation importantly, example, historically strategic as allure Plexium. efficiently the potential
unique published So, help remember will we entirely own validated of XXXX’s own the matter composition data improved entity development us of its molecular guide and patent. considerable amount characteristic XXXX in let’s avadomide But development. is new an with believe its of produced that that the and of significantly
compared fact, help body efficacy activity on learn showed a today’s avadomide resources anti-tumor to can studies, In from work that vast structure Salarius in the preclinical research development focuses developing myeloma. surrounding animal us To DeuteRx we achieve transaction avadomide. with backloading by and to Clearly, in of XXXX increased potential, XXXX improved this multiple milestones.
not XXXX is for initiation solid this registration potential milestone as on until focused we into due With clinic the a a tumors and cancers first XXXX. are treatment the hematological mind, the advancing clinical in fact, trial. in of In XXXX
updates will later additional During year. data providing look XXXX, this an prepare to IND we preclinical we and submission forward for
all about and pipeline. this the While all to to development I further enabling financial Salarius is would happening, details seclidemstat But discuss Officer growth. continuing further Mark of to is continuing advance clinical to Chief which development discuss before opportunities foundation, ask the future, to Financial I strong is Rosenblum, explore our Salarius’ this seclidemstat expand of like Mark?
